Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma

Next Previous
Trial Profile

A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Epacadostat (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms ECHO-110
  • Sponsors Incyte Corporation

Most Recent Events

  • 20 Apr 2026 Protocol has been amended to include five new arms (Experimental: Epacadostat 50 mg+Atezolizumab 1200 mg, Experimental: Epacadostat 75 mg+Atezolizumab 1200 mg, Experimental: Epacadostat 100 mg+Atezolizumab 1200 mg, Experimental: Epacadostat 200 mg+Atezolizumab 1200 mg and Experimental: Epacadostat 300 mg+Atezolizumab 1200 mg) , it has changed from 1 to 6.
  • 01 Aug 2017 According to an Incyte Corporation media release, in June 2017, Incyte and Roche/Genentech decided to close the ECHO-110 trial of epacadostat plus atezolizumab to further enrollment because of slow study recruitment.
  • 01 Aug 2017 Status changed from recruiting to discontinued, according to an Incyte Corporation media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top